Rafael Moleron

Dr. Rafael Moleron

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LFLaura Feeney
Laura Feeney
YJYatin Jain
Yatin Jain
MBMatthew Beasley
Matthew Beasley
ODOlly Donnelly
Olly Donnelly
Anthony KongAnthony Kong
Anthony Kong
RMRobert Metcalf
Robert Metcalf
Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic chemotherapy. Recent phase II studies have reported improved objective response rates (ORR) with the use of the multi-kinase inhibitor lenvatinib. We sought to evaluate real-world experience of R/M ACC patients treated with lenvatinib monotherapy within the UK National Health Service (NHS) to determine the response rates by Response Evaluation Criteria of Solid Tumour (RECIST) and clinical outcomes. Twenty-three R/M ACC patients from eleven cancer centres were included. All treatment assessments for clinical decision making related to drug therapy were undertaken at the local oncology centre. Central radiology review was performed by an independent clinical trial radiologist and blinded to the clinical decision making. In contrast to previously reported ORR of 12–15%, complete or partial response was not observed in any patients. Eleven patients (52.4%) had stable disease and 5 patients (23.8%) had progression of disease as the best overall response. The median time on treatment was 4 months and the median survival from discontinuation was 1 month. The median PFS and OS from treatment initiation were 4.5 months and 12 months respectively. Multicentre collaborative studies such as this are required to evaluate rare cancers with no recommended standard of care therapy and variable disease courses.


25 February 2024 in World Neurosurgery: X
Verified
Journal Article
Open access
DVDamjan Veljanoski
Damjan Veljanoski
RBRaphae Barlas
Raphae Barlas
AJAimun A.B. Jamjoom
Aimun A.B. Jamjoom
JWJames Walkden
James Walkden
GHGraham Horgan
Graham Horgan
AGAnastasios Giamouriadis
Anastasios Giamouriadis
Background: The geographical catchment area served by the Neurosurgical Unit in Aberdeen, Scotland is the largest in the United Kingdom. We examined whether a distance-decay effect on survival exists for patients diagnosed with glioblastoma, who have to travel substantial distances for neurosurgical and oncological treatment in the north of Scotland. Methods: Electronic medical records of adult patients with glioblastoma, referred for treatment between 2007 and 2018, who underwent surgical resection were reviewed. Travel time by car (as a measure of distance travelled) was calculated from the patients’ home to their general practice (GP) and to their main neuro-oncological centre. Results: There were 122 patients; 71 (58.2%) were male and the mean age was 57.8 years. The urban-rural split was 61.5% and 38.5%, respectively. Median driving time to the neuro-oncological centre was 36 min and to the GP this was 6 min. Most patients underwent either sub-total (49.6%) or gross total (46.3%) surgical resection. Post-operative treatments included: radiotherapy only (15.6%), chemotherapy only (6.6%), and chemotherapy with radiotherapy (63.1%). Temozolomide was used in 70.5% of patients. Seventeen patients did not receive any post-operative chemo-radiotherapy. The median survival time was 345 days. There was no statistically significant association between distance travelled and survival time in days. MGMT methylation status, extent of resection, Charlson co-morbidity index and treatment received significantly affected survival. Conclusions: There was no evidence of disadvantage on survival time for patients living further from their neuro-oncological centre compared to those who live nearer.

20 October 2026 in B-ENT
Verified
Journal Article
Closed access
PDF file
FCFergus Cooper
Fergus Cooper
RMRafael Moleron
Rafael Moleron
MSMuhammad Shakeel
Muhammad Shakeel
A patient treated with chemoradiation for a T3 N2b M0 supraglottic squamous cell carcinoma developed regional recurrence at the site of a healed temporary tracheostomy which had been performed over 10 years prior for an unrelated illness requiring intensive care. This phenomenon has not been reported in the literature and raises the hypothesis of tissue healing post-tracheostomy altering the lymphatic drainage of the larynx. The patient was treated with further chemoradiotherapy, surgical resection of the tracheal tumor mass with new tracheostomy formation. The patient continued to be closely followed up and enjoyed a good quality of life without any signs of recurrence, until he died of pneumonia.

12 June 2023 in medRxiv
Verified
Preprint
Open access
PDF file
ATAlekh Thapa
Alekh Thapa
ACAnna Cowell
Anna Cowell
APAdam Louis Peters
Adam Louis Peters
DNDavid J Noble
David J Noble
AJAllan James
Allan James
CWChristina Wilson
Christina Wilson
Objectives: The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence who approved monotherapy alone in England and Wales. We aimed to provide real-world performance data for first-line pembrolizumab-containing treatments for head and neck squamous cell carcinoma (HNSCC) in the palliative setting in Scotland. Materials and Methods: We analysed the electronic records of patients who initiated pembrolizumab-containing treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free survival (PFS), duration of response (DOR), disease control rate (DCR). Data were compared with the KEYNOTE-048 study and clinical factors were evaluated for association with survival. Results: Our cohort included 91 patients (median follow-up 10.8 months). Patient characteristics were similar to the KEYNOTE-048 study though our cohort had a higher proportion of patients with newly diagnosed, non-metastatic disease. For patients receiving monotherapy (n=76), 12-month and 24-month OS was 45% and 27%, respectively. For patients receiving pembrolizumab-chemotherapy (n=15), 12-month OS was 60% (24-month OS had not yet been reached). Experiencing ≥1 irAE (versus no irAEs), of any grade, was associated with favourable OS and PFS for patients receiving monotherapy in both univariable log-rank analysis (median OS 17.4 months versus 8.6 months, respectively, P=0.0033; median PFS 10.9 months versus 3.0 months, respectively, P<0.0001) and multivariable analysis (Cox proportional hazards regression: OS HR: 0.31, P=0.0009; PFS HR: 0.17, P<0.0001). Conclusion: Our real-world data support the KEYNOTE-048 study findings and the value of combination treatment options. Additionally, our data show irAEs of any grade, as reported in routine clinical records, are associated with better outcomes in this patient group, adding to the growing body of evidence showing irAEs are generally a positive marker of PD-L1 inhibitor response.